- Home
- RLX vs OGN Comparison
RLX vs OGN Comparison
Compare RLX & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLX
- OGN
- Stock Information
- Founded
- RLX 2018
- OGN 1923
- Country
- RLX China
- OGN United States
- Employees
- RLX N/A
- OGN N/A
- Industry
- RLX Medicinal Chemicals and Botanical Products
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- RLX Health Care
- OGN Health Care
- Exchange
- RLX Nasdaq
- OGN Nasdaq
- Market Cap
- RLX 2.8B
- OGN 2.5B
- IPO Year
- RLX 2021
- OGN N/A
- Fundamental
- Price
- RLX $2.24
- OGN $10.21
- Analyst Decision
- RLX Hold
- OGN Hold
- Analyst Count
- RLX 1
- OGN 4
- Target Price
- RLX $2.25
- OGN $18.00
- AVG Volume (30 Days)
- RLX 2.8M
- OGN 3.7M
- Earning Date
- RLX 08-15-2025
- OGN 08-05-2025
- Dividend Yield
- RLX 0.45%
- OGN 0.78%
- EPS Growth
- RLX N/A
- OGN N/A
- EPS
- RLX 0.07
- OGN 2.88
- Revenue
- RLX $369,684,697.00
- OGN $6,294,000,000.00
- Revenue This Year
- RLX $27.26
- OGN N/A
- Revenue Next Year
- RLX $19.61
- OGN $1.11
- P/E Ratio
- RLX $32.50
- OGN $3.55
- Revenue Growth
- RLX 68.72
- OGN N/A
- 52 Week Low
- RLX $1.50
- OGN $8.01
- 52 Week High
- RLX $2.69
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- RLX 49.38
- OGN 58.77
- Support Level
- RLX $2.24
- OGN $9.55
- Resistance Level
- RLX $2.29
- OGN $10.22
- Average True Range (ATR)
- RLX 0.06
- OGN 0.30
- MACD
- RLX -0.02
- OGN 0.04
- Stochastic Oscillator
- RLX 3.33
- OGN 93.64
About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.